Full-Time

Director – Clinical Development

Confirmed live in the last 24 hours

Pliant Therapeutics

Pliant Therapeutics

51-200 employees

Develops treatments for fibrotic diseases

Biotechnology
Healthcare

Compensation Overview

$320k - $335kAnnually

Senior

San Bruno, CA, USA

Hybrid position requiring 3 days/week at Pliant in South San Francisco.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • M.D. degree with at least 3-5 years of clinical research and development experience within pharmaceutical/biotech industry
  • Start-up/small company experience a plus; can-do attitude is essential
  • Clinical development experience in an industry setting ranging from Phases 1 to 4, including first-in-human and pivotal studies
  • Experience with rare diseases, fibrotic diseases in the liver (e.g., PSC, PBC, NASH) and/or lung (e.g., IPF, ILD, cystic fibrosis) is a plus
  • Experience with development of clinical study related documents (e.g., clinical trial protocols, Investigator’s Brochures, clinical study reports)
  • Knowledge of clinical trial methodology, statistics, regulatory and compliance requirements governing clinical trials, including GCP
  • High integrity and the ability to bring out the best in others, intellectually and interpersonally
  • Demonstrated strategic and critical thinking, dynamic leadership and team-building skills; as well as the ability to perform effectively in an adaptive environment
  • Ability to lead directly and by influence, including strong problem-solving, conflict resolution, and analytical skills
  • Able to facilitate collaborative discussions among groups with diverse technical expertise and varying opinions and drive decisions on complex issues
Responsibilities
  • Act as the Sponsor’s Medical Monitor in close collaboration with clinical operations and CROs, responsible for conducting clinical studies in compliance with the protocol, interacting with study investigators and responding to protocol/medical questions related to participant eligibility, concomitant medications, safety issues and toxicity management
  • Participate as a standing and/or ad hoc member in various clinical sub-teams (e.g., study execution team [SET], clinical study team [CST]) relevant to assigned molecule(s)/indication(s); support the CST lead with cross-functional integration, coordination, and alignment to enable effective and efficient clinical development plan execution
  • Ensure that clinical study is conducted in compliance to GCP, company SOPs, governing laws, and regulations; review outstanding clinical or GCP issues, report and address issues across the study and, provide the study team with medical expertise during key activities
  • Maintain the highest standards and levels of scientific and clinical knowledge in the specific therapeutic and disease area(s) of assignment
  • Contribute to the design and development of clinical study protocols (Phases 1 to 3) from a concept sheet to a full protocol; participate in the review and finalization process with clinical operations, medical writing, regulatory affairs, clinical pharmacology, and other key cross-functional contributors
  • In close collaboration with clinical operations, participate in the identification and selection of CROs, appropriate external investigators and sites
  • Oversee and participate to protocol training, produce relevant training materials, and represent clinical development in Investigator meetings
  • Coordinate with the study team to review and approve study processes and deliverables and participate in development of informed consent forms (ICF), case report forms (CRF), safety management plans, medical monitoring plans, statistical analysis plans (SAP) and clinical study reports (CSR)
  • Lead the development of clinical responses to protocol questions by healthy authorities, independent review boards and ethical committees, in collaboration with regulatory affairs and/or clinical operations
  • Collaborate with clinical teams to measure and monitor study progress against objectives and plans, including any variances, and proactively communicate any issues, challenges and potential strategies to resolve such
  • Review patient profiles, and study level data; review coding of adverse events (AEs), concomitant medications and protocol deviations
  • In close collaboration with clinical operations, data management, biometrics and CRO, participate in all reviews and procedures required for database lock
  • Review study data outputs to provide the most comprehensive clinical interpretation, for interim and final study reporting; develop topline study reports in collaboration with biometrics and relevant stakeholders (e.g., clinical pharmacology, translational sciences, etc.)
  • Participate in the development and implementation of scientific communication and publication strategies for ongoing and completed studies
  • Engage with principal investigators and key opinion leaders at advisory boards, major medical meetings, congresses, and other scientific events
  • Collaborate cross-functionally in development of clinical sections of investigator brochures (IB), annual safety reports, IND and IMPD updates
  • Review of clinical data generated by data listings or statistical analyses outputs for assigned studies and, present findings at quarterly drug safety reviews, as needed
  • Support pharmacovigilance process; review individual data with Serious Adverse Events (SAEs) and important medical events; author and/or review all safety narratives and related regulatory reports (CIOMS, MedWatch)

Pliant Therapeutics develops treatments for fibrotic diseases, which cause thickening and scarring of connective tissue, leading to organ dysfunction. Their products work by targeting the biological mechanisms behind fibrosis, particularly through the inhibition of integrins, proteins that help cells stick together and communicate. This focus allows Pliant to create specific and effective therapies for various fibrotic conditions. Unlike many competitors, Pliant emphasizes a deep understanding of fibrosis and integrin biology, which informs their drug development process. The company's goal is to stop the progression of fibrotic diseases and restore normal organ function, ultimately improving the lives of patients affected by these conditions.

Company Stage

IPO

Total Funding

$201.4M

Headquarters

San Francisco, California

Founded

2015

Growth & Insights
Headcount

6 month growth

6%

1 year growth

12%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Pliant's accelerated development of bexotegrast for IPF and positive Phase 2a trial results indicate strong potential for successful market entry.
  • The company's participation in high-profile investor events and scientific congresses enhances its visibility and credibility in the biotech community.
  • Recent strategic appointments, including a new Chief Development Officer and Chief Regulatory Officer, bolster Pliant's leadership team and operational capabilities.

What critics are saying

  • The high costs and long timelines associated with drug development pose financial risks, especially if clinical trials do not meet endpoints.
  • The competitive landscape in biopharmaceuticals, particularly in fibrosis treatment, requires Pliant to continuously innovate to maintain its edge.

What makes Pliant Therapeutics unique

  • Pliant Therapeutics focuses specifically on fibrotic diseases, leveraging deep expertise in fibrosis and integrin biology, unlike competitors with broader therapeutic areas.
  • Their targeted approach to integrin inhibition offers a unique mechanism of action that sets them apart from other fibrosis treatments.
  • Pliant's commitment to rigorous clinical trials and data-driven development ensures high standards of efficacy and safety, distinguishing them in the biopharmaceutical market.

Help us improve and share your feedback! Did you find this helpful?